BDBM165320 US10604504, Example 116::US11623921, Example 116::US9688629, 116::US9802915, Example 116::US9920031, Example 116

SMILES CC#CC(=O)N[C@H]1CCCN(C1)c1ccc(C(N)=O)c2[nH]c(C)c(C)c12

InChI Key

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 165320   

TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMpH: 7.4 T: 2°CAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMAssay Description:Inhibition of recombinant human BTK using fluoresceinated peptide as substrate after 60 mins fluorescence assayMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  40nMAssay Description:Inhibition of BTK in human Ramos B cells assessed as reduction in BCR-stimulated calcium flux after 1 hr in dark condition measured for 180 secMore data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
Bristol-Myers Squibb

US Patent
LigandPNGBDBM165320(US10604504, Example 116 | US11623921, Example 116 ...)
Affinity DataIC50:  0.520nMAssay Description:To V-bottom 384-well plates were added test compounds, human recombinant Btk (1 nM, Invitrogen Corporation), fluoresceinated peptide (1.5 μM), A...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent